文献速递眼底病与葡萄膜炎

抗血管内皮生长因子治疗与增生型糖尿病视网膜病变眼牵引性视网膜脱离风险:五项DRCR视网膜网络随机临床试验的汇总分析

ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY AND RISK OF TRACTION RETINAL DETACHMENT IN EYES WITH PROLIFERATIVE DIABETIC RETINOPATHY: Pooled Analysis of Five DRCR Retina Network Randomized Clinical Trials.
PubMed 文献 · Retina · 2020-01-01

该汇总分析纳入五项DRCR视网膜网络方案中早期治疗糖尿病视网膜病变研究分级≥61且未计划立即玻璃体切割的增生型糖尿病视网膜病变眼,比较对照组(396眼)与抗血管内皮生长因子组(487眼)1年内牵引性视网膜脱离风险,结果两组风险无显著差异(HR=0.95,95%CI 0.54-1.66,P=0.86)。

要点

  • 抗血管内皮生长因子组1年牵引性视网膜脱离累积概率4.8%,对照组6.8%,HR=0.95(95%CI 0.54-1.66,P=0.86)。
  • 因牵引性视网膜脱离行玻璃体切割的累积概率抗血管内皮生长因子组2.2%,对照组4.4%(P=0.19)。
  • 各糖尿病视网膜病变严重程度分层内牵引性视网膜脱离及玻璃体切割比例相似。

核心结论

  • 这些发现不支持以下假设:对于与五项未计划立即玻璃体切割的DRCR视网膜网络方案中所入组相似的增生型糖尿病视网膜病变眼,因糖尿病黄斑水肿或增生型糖尿病视网膜病变行抗血管内皮生长因子治疗会增加牵引性视网膜脱离风险。

研究设计与样本

  • 对五项DRCR视网膜网络方案(I、J、N、S或T)中的增生型糖尿病视网膜病变眼进行汇总分析,纳入早期治疗糖尿病视网膜病变研究分级≥61且未计划立即玻璃体切割的眼。
  • 对照组396眼接受激光光凝、假注射或玻璃体腔生理盐水,抗血管内皮生长因子组487眼,主要结局为随机分组后1年内研究者识别的牵引性视网膜脱离。

主要发现

  • 1年牵引性视网膜脱离累积概率对照组为6.8%(95%CI 4.6%-9.9%,25例事件),抗血管内皮生长因子组为4.8%(95%CI 3.2%-7.3%,22例事件),HR=0.95(95%CI 0.54-1.66,P=0.86)。
  • 因牵引性视网膜脱离行玻璃体切割的累积概率对照组为4.4%(16例事件),抗血管内皮生长因子组为2.2%(9例事件),P=0.19。
  • 各糖尿病视网膜病变严重程度分层内牵引性视网膜脱离及因牵引性视网膜脱离行玻璃体切割的比例相似。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To investigate whether anti-vascular endothelial growth factor (anti-VEGF) for diabetic macular edema or proliferative diabetic retinopathy (PDR) increases the risk of traction retinal detachment (TRD) among eyes with PDR. METHODS: Pooled analysis of PDR eyes from Protocols I, J, N, S, or T with Early Treatment Diabetic Retinopathy Study level ≥61 (prompt vitrectomy was not planned) randomly assigned to the control group (laser photocoagulation, sham, or intravitreal saline; 396 eyes) or anti-VEGF (487 eyes). The primary outcome was investigator-identified TRD within 1 year of randomization. RESULTS: The 1-year cumulative probability of TRD was 6.8% (95% confidence interval: 4.6%-9.9%, 25 events) in control-group eyes and 4.8% (95% confidence interval: 3.2%-7.3%, 22 events) in anti-VEGF group eyes (hazard ratio = 0.95 [95% confidence interval: 0.54-1.66, P = 0.86]). The cumulative probability of vitrectomy for TRD was 4.4% (16 events) in control-group eyes and 2.2% (9 events) in anti-VEGF group eyes (P = 0.19). Percentage with TRD and vitrectomy for TRD were similar within strata of diabetic retinopathy severity. CONCLUSION: These findings do not support the hypothesis that anti-VEGF therapy for diabetic macular edema or PDR increases the risk of TRD among eyes with PDR similar to those enrolled in five DRCR Retina Network protocols for which prompt vitrectomy was not planned.

来源:Retina,查看原文。版权归原作者所有。

引用

  1. Bressler NM, Beaulieu WT, Bressler SB, et al. ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY AND RISK OF TRACTION RETINAL DETACHMENT IN EYES WITH PROLIFERATIVE DIABETIC RETINOPATHY: Pooled Analysis of Five DRCR Retina Network Randomized Clinical Trials. Retina. 2020. PMID: 31567817. doi:10.1097/IAE.0000000000002633

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。